Denali Therapeutics and Royalty Pharma announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Tividenofusp alfa is Denali's lead investigational TransportVehicle TM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome).
The agreement includes specific terms for royalty payments and milestones to be met by Denali.
Partnership with Royalty Pharma
Denali Therapeutics partnered with Royalty Pharma to secure funding for their innovative therapy, tividenofusp alfa.
Royalty Funding Agreement
Royalty Pharma will make an initial payment of $200 million to Denali, with an additional $75 million contingent on European Medicines Agency approval of tividenofusp alfa.
Royalty Percentage
Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa from Denali.
- The funding agreement provides Denali with the necessary financial support to advance their development programs and prepare for the launch of tividenofusp alfa.
- Royalty Pharma's investment acknowledges the potential of tividenofusp alfa for addressing the unmet needs in Hunter syndrome, impacting the lives of patients with cognitive and physical manifestations of the disease.
The collaboration between Denali Therapeutics and Royalty Pharma marks an important milestone in securing funding for the development and commercialization of tividenofusp alfa, offering hope to patients with Hunter syndrome and showcasing the potential of innovative biotechnology solutions.